Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Executive Summary
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
You may also be interested in...
PhRMA Played Supporting Role In Case Questioning DTC Advertising In Product Liability Disputes
Association presented oral argument before the Washington State Supreme Court, which certified that drug manufacturers who advertise directly to consumers are not prohibited from using the learned intermediary doctrine as a defense to claims of inadequate warning of a product’s risks.
Pitching Drugs To Physicians: Disclosing Limitations Of Clinical Data May Be Beneficial
US FDA study finds that sales aids for oncology drugs that disclose a study’s data limitations and clinical uncertainty can lead to more appropriate assessments of the data by physicians but does not affect their overall perceptions of a drug’s benefits.
US FDA’s Rx Drug Promo Study Answers $798,000 Question
Viewers spend more time on print ads that have more lengthy important safety information or a brief summary but impact on understanding is unclear, OPDP study finds. Another study finds exaggerated images of drug benefits in TV ads unsurprisingly can mislead consumers.